Literature DB >> 23572565

In need of remedy: US policy for compensating injured research participants.

Elizabeth R Pike1.   

Abstract

There is an emerging ethical consensus that injured research participants should receive medical care and compensation for their research-related injuries. This consensus is premised on notions of beneficence, distributive justice, compensatory justice and reciprocity. In response, countries around the world have implemented no-fault compensation systems to ensure that research participants are adequately protected in the event of injury. The United States, the world's leading sponsor of research, has chosen instead to rely on its legal system to provide injured research participants with medical care and compensation. This article argues that US reliance on its legal system leaves injured research participants unprotected in the event of injury. Nearly every injured research participant will have difficulty receiving compensation in court, and certain classes of research participants will be barred from receiving compensation altogether. The United States' outlier status also threatens to impede US-sponsored multinational research, potentially delaying important biomedical advances. To rectify this injustice, researchers, Institutional Review Boards, sponsors and research institutions should advocate systematic no-fault compensation in the United States to bring US law into accord with global ethical norms and ensure that injured research participants are adequately protected.

Entities:  

Keywords:  Law; Public Policy; Research Ethics; Tort Law

Mesh:

Year:  2013        PMID: 23572565     DOI: 10.1136/medethics-2012-100771

Source DB:  PubMed          Journal:  J Med Ethics        ISSN: 0306-6800            Impact factor:   2.903


  2 in total

1.  Unequal treatment of human research subjects.

Authors:  David B Resnik
Journal:  Med Health Care Philos       Date:  2015-02

2.  Disparate compensation policies for research related injury in an era of multinational trials: a case study of Brazil, Russia, India, China and South Africa.

Authors:  George Rugare Chingarande; Keymanthri Moodley
Journal:  BMC Med Ethics       Date:  2018-02-17       Impact factor: 2.652

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.